EMA Grants PRIME Designation to Iopofosine I-131 for Waldenström Macroglobulinemia

The European Medicines Agency has granted Priority Medicines designation to iopofosine I-131 for use in patients with Waldenström macroglobulinemia in patients who previously received at least 2 treatment regimens.

Related Keywords

United States ,James Caruso ,Cellectar Biosciences ,European Union ,European Medicines Agency Priority ,European Medicines Agency ,Cellectar Biosciences Inc ,Priority Medicines ,Fema ,Prime Designation ,Iopofosinei 131 ,Waldenstrom Macroglobulinemia ,Clr 131 ,Clover 1 Trial ,Fast Track Designation ,Priority Medicines Designation ,